Skip to content

    Sigachi Industries Limited

    SIGACHI
    Healthcare·24 Oct 2025
    Management Summary

    Sigachi Industries reported a total operating income of Rs.110.5 crores and a net profit of Rs.10.5 crores for Q2 FY26, despite a temporary disruption at its Hyderabad facility. The company is actively expanding its MCC capacity by 12,000 MTPA at Dahej and is on track to commission its CCS plant by Q3 FY27. A new API R&D center is now fully operational, and management expects to recover approximately Rs.70 crores from insurance claims related to the incident.

    Highlights

    5
    • Total operating income reached Rs.110.5 crores in Q2 FY26.

    • Net profit stood at Rs.10.5 crores, achieving a PAT margin of 9.59%.

    • MCC capacity expansion of 12,000 MTPA at Dahej is fast-tracked, increasing total capacity to 30,000 MTPA by Q3 FY27.

    • New API R&D Center in Hyderabad is fully operational, consolidating API development and analytical capabilities.

    • CCS project is on schedule for commissioning by Q3 FY27, representing an important step into high-value excipients.

    Concerns

    3
    • Hyderabad facility incident caused temporary disruption, with restoration progressing in phases and future course to be finalized post-investigation.

    • Gross margin fell by approximately 170 bps year-on-year due to increased transportation costs from shifting operations post-incident.

    • Promoter share pledging and subsequent sale for repayment raised concerns among individual investors regarding corporate governance.

    Key financials

    Single quarter

    05 metrics
    1. 01Total Operating Income₹110.5 Cr
    2. 02EBITDA₹7.5 Cr
    3. 03EBITDA Margin6.8%
    4. 04Net Profit₹10.5 Cr
    5. 05PAT Margin9.6%

    Segment breakdown

    • MCC₹66.4 Cr67.8%
    • O&M₹13.17 Cr13.4%
    • API₹18.41 Cr18.8%
    Donut· Share of Revenue

    Capital allocation

    2
    medium confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Guidance & targets

    10
    CategoryTargetPriority
    Capacity
    Total MCC Capacity
    30,000 MTPA
    High
    Capacity
    CCS Plant Commissioning
    Commissioned
    High
    Revenue
    Revenue from new 12,000 MTPA MCC capacity
    Rs.250 crores
    High
    Revenue
    Total Operating Income
    not less than 575 crores
    Medium
    EBITDA Margin
    EBITDA Margin for new Dahej facility
    minimum 20%
    High
    EBITDA Margin
    EBITDA Margin for O&M segment
    20%-22%
    High
    EBITDA Margin
    EBITDA Margin for CCS segment
    up to 30%
    High
    Capacity Utilization
    Existing capacity utilization
    nearly 90%
    High
    Capacity Utilization
    New capacity utilization (12,000 MTPA)
    50%
    Medium
    API Approvals
    CEP approvals for API segment
    Cleared
    Medium

    What to watch in Q3 FY26

    5

    Hyderabad facility resumption clarity

    by end of Q3 FY26
    CurrentInvestigation ongoing, restoration in phases
    TargetClarity on resumption

    Why it matters

    Resumption of the Hyderabad facility is crucial for full operational capacity and reduced reliance on other plants.

    It is, as of now, the safety protocol and all the sites, even here also, after seeking the regulatory approvals, then we will go ahead. Maybe we will get clarity by the end of this quarter.

    Risks & concerns

    4
    RiskSeverity

    Hyderabad facility incident and operational disruption

    A localized dust explosion at the Pashamylaram facility caused temporary production relocation and ongoing investigation, impacting Q2 operations.Management acknowledged

    high

    Gross margin compression due to operational shift

    Gross margin declined by ~170 bps YoY due to increased transportation costs from shifting production to other facilities post-Hyderabad incident.Management acknowledged

    medium

    Promoter share pledging and sales impacting investor confidence

    Analyst raised concerns about promoter share sales linked to loan against shares (LAS) renewal, which management explained as repayment driven, with no plans for further reduction.Analyst downplayed

    medium

    Potential blacklisting or loss of state incentives due to incident

    Analyst cited a news article suggesting potential blacklisting or loss of incentives, to which management stated they had no information.Analyst not addressed

    low

    Q&A highlights

    7

    “So, in the regulated markets, Chinese MCC players do not stand a chance. Yes, they have not stood chance and regulated market is much more stringent and we have not seen them competing against us on any particular customer base or targeted markets.”

    Management asserts that Chinese competitors are not a threat in regulated markets due to stringent requirements, implying a competitive edge for Sigachi.

    asked by Rehan Syed

    3 min read6 chapters

    Detailed Narrative

    01

    Hyderabad Incident and Operational Resilience

    Sigachi Industries faced a localized dust explosion at its Pashamylaram facility in Hyderabad, leading to temporary disruption. Production has been relocated to Dahej and Jhagadia facilities to ensure uninterrupted supply to customers. The company has provided interim compensation and ex gratia financial assistance to affected families, taking full responsibility for medical expenses. The future course for the facility will be finalized post-investigation, with clarity expected by the end of Q3 FY26. Management expects to receive approximately Rs.70 crores from insurance claims, covering fixed assets, loss of profit, and stock loss, with an ad hoc amount anticipated in Q3 FY26.

    02

    Capacity Expansion and Future Growth Initiatives

    The company is aggressively pursuing capacity expansion, fast-tracking a 12,000 MTPA MCC expansion at its Dahej SEZ facility. This will increase total MCC capacity to 30,000 MTPA, with commissioning targeted by Q3 FY27. This new capacity is expected to generate Rs.250 crores in revenue at full utilization with a minimum 20% EBITDA margin. Additionally, the CCS project is on schedule for commissioning by Q3 FY27, marking a strategic entry into high-value excipients with an anticipated EBITDA margin of up to 30%. The company aims to utilize nearly 90% of its existing capacity by the end of FY26 and expects about 50% utilization of new capacities by H1 FY27.

    03

    API Segment Development and Regulated Market Focus

    Sigachi has achieved a significant milestone with its new API R&D Center in Hyderabad becoming fully operational. This center consolidates API development and analytical capabilities, aiming to improve speed-to-market and integration with manufacturing. The company is actively pursuing approvals from the European Directorate of Quality and Medicine for its API portfolio, with CEP clearances expected within the next two to three quarters. This strategic focus is intended to strengthen Sigachi's position in regulated markets and expand its API portfolio.

    04

    Q2 FY26 Financial Performance and Margin Dynamics

    For Q2 FY26, Sigachi reported a total operating income of Rs.110.5 crores. EBITDA stood at Rs.7.5 crores, resulting in an EBITDA margin of 6.78%. Net profit for the quarter was Rs.10.5 crores, with a PAT margin of 9.59%. The MCC segment contributed Rs.66.4 crores, O&M Rs.13.17 crores, and API Rs.18.41 crores. The gross margin saw a year-on-year decline of approximately 170 bps, primarily attributed to increased transportation costs incurred from shifting operations post-Hyderabad incident. Management expects stabilization in Q3 and Q4.

    05

    Raw Material and Pricing Environment

    Despite some pulp price reductions (around $50 per ton for certain grades), MCC selling prices have increased. Management attributes this to strong demand and a prevailing shortfall in MCC supply in the market. This dynamic has allowed Sigachi to maintain or increase realizations. The company noted that Chinese MCC players are not competitive in the more stringent regulated markets, where Sigachi operates, due to higher quality and compliance requirements.

    06

    Capital Structure and Shareholder Confidence

    The company clarified that the recently announced shareholder approval for Rs.1,000 crores is for broader borrowing limits (up to Rs.700-800 crores) to seize future opportunities, not an immediate debt raise. Management emphasized that this is a common practice for companies to have higher approved limits. Concerns regarding promoter share pledging and subsequent sales were addressed, with management explaining these were due to loan against shares (LAS) renewal and repayment, asserting no plans for further stake reduction. They reiterated their commitment to upholding the highest standards of safety and compliance across all facilities.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.